



07-07-05

ITW

Practitioner's Docket No. MBIO99-017CP2CN1M

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pan, Yang and Lora, Jose M.  
Application No.: 10/601,368 Group No.: 1644  
Filed: June 23, 2003 Examiner: Haddad, Maher M.  
For: NUCLEIC ACID ENCODING INTEGRIN ALPHA SUBUNIT

Mail Stop Petition  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## TRANSMITTAL

1. Transmitted herewith for this application is/are:
  - a. This Transmittal (3 pages - in duplicate);
  - b. Authorization to Act in a Representative Capacity for Mario Cloutier (2 pages);
  - c. Petition and Fee for Extension of Time (2 pages - in duplicate);
  - d. Statement of Limited Recognition under 37 CFR §11.9 (b) for Mario Cloutier (1 page); and
  - e. Return Postcard.

## STATUS

2. Applicant is other than a small entity.

## CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

## MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
37 C.F.R. SECTION 1.8(a)

## 37 C.F.R. SECTION 1.10\*

- ☐ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Addressee"  
Mailing Label No. EV656199218US

## TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office

Signature

Carolyn Willey

(type or print name of person certifying)

Date: July 5, 2005

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**PETITION FOR EXTENSION OF TIME**

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(3)) for a \_\_\_\_\_ month extension:

Fee: \$0.00

Extension fee due with this request \$0.00

If an additional extension of time is required, please consider this a petition therefor.

**FEE FOR CLAIMS**

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

| (Col. 1)   | (Col. 2)                              | (Col. 3)      | OTHER THAN A<br>SMALL ENTITY |          |            |        |
|--|---------------------------------------|---------------|------------------------------|----------|------------|--------|
| Claims<br>Remaining After<br>Amendment             | Highest No.<br>Previously Paid<br>For | Present Extra | Rate                         |          | Addit. Fee |        |
| Total  | Minus                                 | =             | 0                            | \$50.00  | =          | \$0.00 |
| Indep.   | Minus                                 | =             | 0                            | \$200.00 | =          | \$0.00 |
| First Presentation of Multiple Dependent<br>Claims |                                       |               | 0                            | \$360.00 | =          | \$0.00 |
| Total<br>Addit. Fee                                |                                       |               |                              |          |            | \$0.00 |

Total additional fee for claims required \$0.00

**FEE PAYMENT**

5. Charge Account No. 501668 the sum of \$0.00 (which includes the \$0.00 extension fee and the \$0.00 additional fee for claims). A duplicate of this transmittal is attached.

**FEE DEFICIENCY**

6. If any additional extension and/or fee is required, charge Account No. 501668.  
If any additional fee for claims is required, charge Account No. 501668.

**Practitioner's Docket No. MBIO99-017CP2CN1M**


7. Correspondence Address

Direct all future correspondence to:

**Customer Number 30405**  
**OR**  
**Intellectual Property Department**  
**MILLENNIUM PHARMACEUTICALS, INC.**  
40 Landsdowne Street  
Cambridge, MA 02139

July 5, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By   
Mario Cloutier  
Limited Recognition Under 37 C.F.R. § 11.9(b)  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone – (617) 577-3522  
Facsimile – (617) 551-8820



Practitioner's Docket No. **MBIO99-017CP2CN1M**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Pan, Yang and Lora, Jose M.  
Application No.: 10/601,368                      Group No.: 1644  
Filed: June 23, 2003                      Examiner: Haddad, Maher M.  
For: NUCLEIC ACID ENCODING INTEGRIN ALPHA SUBUNIT

**Mail Stop Petition**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**AUTHORIZATION TO ACT IN A REPRESENTATIVE CAPACITY**

Dear Sir:

The practitioner named below is authorized to conduct interviews and has the authority to bind the principal concerned. Furthermore, the practitioner is authorized to file correspondence in the above-identified application pursuant to 37 CFR 1.34:

Mario Cloutier  
Limited Recognition Under 37 CFR §11.9(b)  
Customer Number 30405 or  
Millennium Pharmaceuticals, Inc.  
40 Landsdowne Street  
Cambridge, MA 02139

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

☐ with sufficient postage as first class mail.


☒ as "Express Mail Post Office to Addressee"  
Mailing Label No. EV656199218US

**TRANSMISSION**

☐ transmitted by facsimile to the Patent and Trademark Office.

Date: July 5, 2005

Signature

  
Carolyn Willey

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**This is not a Power of Attorney to the above-named practitioner.**

Accordingly, the practitioner named above does **not** have authority to sign a request to change the correspondence address, a request for an express abandonment, a disclaimer, a power of attorney, or other document requiring the signature of the applicant, assignee of the entire interest or an attorney of record. If appropriate, a separate Power of Attorney to the above-named practitioner should be executed and filed in the United States Patent and Trademark Office.

Please continue to forward all written and telephonic communications to Jean M. Silveri at the address and telephone number listed below.


**SIGNATURE of Practitioner of Record**

July 5, 2005

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Jean M. Silveri

Registration No. 39,030

40 Landsdowne Street

Cambridge, MA 02139

Telephone – (617) 679-7336

Facsimile – (617) 551-8820




**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATE PATENT AND TRADEMARK OFFICE**

**LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)**

Mario Cloutier is hereby given limited recognition under 37 CFR, 11.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

**Expires: December 29, 2006**

  
\_\_\_\_\_  
Harry I. Moatz  
Director of Enrollment and Discipline